Sep 28, 2019 / 05:00PM GMT
Operator
My name is Mary, and I will be your conference facilitator today for Amgen's Conference Call from the 2019 European Society for Medical Oncology in Barcelona. (Operator Instructions) I would now like to introduce Mr. John Shutter, Director of Investor Relations. Please go ahead, sir.
John Shutter -
Thank you, Mary, and thanks, everyone, for joining us today.
As you know, we provided a clinical update at ESMO on AMG 510, our first-in-class KRAS G12C inhibitor in patients with solid tumors that harbor this mutation.
I'm joined today by Dr. David Reese, our Executive Vice President of Research and Development; and by Dr. Greg Friberg, who's our Vice President of Global Oncology Development.
Dave will make some opening comments, and Greg will step through the data that were presented today, after which we'll take your questions.
And for the Q&A, I'm especially pleased to welcome Dr. Marwan Fakih, who is Professor in the Department of Medical Oncology and Therapeutics Research as well as Co-Director of the Gastrointestinal Cancer
Amgen Inc Investor Call at European Society for Medical Oncology (ESMO) Transcript
Sep 28, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers